Referanslar

1. Jakubiec L, Chirokoff V, Abdallah M, et al. The Executive Functioning Paradox in Substance Use Disorders. Biomedicines. 2022;10(11):2728. [Crossref]  [PubMed]  [PMC]
2. Volkow ND, Blanco C. Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry. 2023;22(2):203-229. [Crossref]  [PubMed]  [PMC]
3. American Psychiatric Association. Diagnostic and Statisti cal Manual of Mental Disorders. Fifth Edition. American Psychiatric Association; 2013. [Crossref]  [PubMed]
4. Over 3 million annual deaths due to alcohol and drug use, majority among men PAHO/WHO | Pan American Health Organization. June 25, 2024. Accessed February 23, 2025.
5. Ciucă Anghel DM, Nițescu GV, Tiron AT, Guțu CM, Baconi DL. Understanding the Mechanisms of Action and Effects of Drugs of Abuse. Molecules. 2023;28(13):4969. [Crossref]  [PubMed]  [PMC]
6. Abuse NI on D. Drugs, Brains, and Behavior: The Science of Addiction: Drugs and the Brain | NIDA. July 6, 2020. Accessed February 23, 2025. [Crossref]  [PubMed]
7. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39(1):32-41. [Crossref]  [PubMed]
8. UNODC World Drug Report 2024: Harms of world drug problem continue to mount amid expansions in drug use and markets. United Nations : Information Service Vienna. Accessed February 23, 2025. [Crossref]
9. Degenhardt L, Charlson F, Ferrari A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987-1012. [Crossref]  [PubMed]  [PMC]
10. Abuse NI on D. Commonly Used Drugs Charts | National Institute on Drug Abuse (NIDA). September 19, 2023. Accessed February 23, 2025.
11. Herlinger K, Lingford-Hughes A. Opioid use disorder and the brain: a clinical perspective. Addiction. 2022;117(2):495-505. [Crossref]  [PubMed]
12. Spiller KJ, Bi G, He Y, Galaj E, Gardner EL, Xi Z. Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats. Br J Pharmacol. 2019;176(9):1268-1281. [Crossref]  [PubMed]  [PMC]
13. Tai S, Fantegrossi WE. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. Curr Addict Rep. 2014;1(2):129-136. [Crossref]  [PubMed]  [PMC]
14. Ikeda S, Kinoshita T. Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens. Psychiatry Clin Neurosci Rep. 2024;3(2):e196. [Crossref]  [PubMed]
15. Grob CS, De Rios MD. Hallucinogens and Related Compounds. In: Rosner R, ed. Clinical Handbook of Adolescent Addiction. 1st ed. Wiley; 2013:213-222. [Crossref]  [PubMed]
16. Bozabali S, Ülger Z, Levent E, Özyürek AR. Uçucu madde bağımlısı bir gençte görülen atrial flutter. Ege Tıp Derg. 2017;56(3):145-147. [Crossref]
17. Harvey PD. Domains of cognition and their assessment. Dialogues Clin Neurosci. 2019;21(3):227-237. [Crossref]  [PubMed]  [PMC]
18. Ramey T, Regier PS. Cognitive impairment in substance use disorders. CNS Spectr. 2019;24(1):102-113. [Crossref]  [PubMed]  [PMC]
19. Erga AH, Hetland J, Braatveit K. Patients with cognitive deficits and substance use disorders, a clinical population in need of focused attention. Front Psychiatry. 2023;14:1281914. [Crossref]  [PubMed]  [PMC]
20. Gould TJ. Addiction and cognition. Addict Sci Clin Pract. 2010;5(2):4-14.
21. Copenhaver MM, Sanborn V, Shrestha R, Mistler CB, Sullivan MC, Gunstad J. Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment. Drug Alcohol Depend. 2021;224:108726. [Crossref]  [PubMed]  [PMC]
22. Schroder E, Dousset C, Noel X, Kornreich C, Campanella S. Increased Neural Activity in Hazardous Drinkers During High Workload in a Visual Working Memory Task: A Preliminary Assessment Through Event-Related Potentials. Front Psychiatry. 2019;10:248. [Crossref]  [PubMed]  [PMC]
23. Ajmera N, Collins PF, Weiss H, Luciana M. Initiation of Moderately Frequent Cannabis use in Adolescence and Young Adulthood is Associated with Declines in Verbal Learning and Memory: A Longitudinal Comparison of Preversus Post-Initiation Cognitive Performance. J Int Neuropsychol Soc. 2021;27(6):621-636. [Crossref]  [PubMed]  [PMC]
24. Meier MH, Caspi A, R. Knodt A, et al. Long-Term Cannabis Use and Cognitive Reserves and Hippocampal Volume in Midlife. Am J Psychiatry. 2022;179(5):362-374. [Crossref]  [PubMed]  [PMC]
25. Renard J, Sanger N, Gabrys R. Clearing the Smoke on Cannabis. [Crossref]
26. Kuźma E, Llewellyn DJ, Langa KM, Wallace RB, Lang IA. History of Alcohol Use Disorders and Risk of Severe Cognitive Impairment: A 19-Year Prospective Cohort Study. Am J Geriatr Psychiatry. 2014;22(10):1047-1054. [Crossref]  [PubMed]  [PMC]
27. Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. Exp Clin Psychopharmacol. 2012;20(5):420-429. [Crossref]  [PubMed]
28. Casey BJ, Jones RM. Neurobiology of the Adolescent Brain and Behavior: Implications for Substance Use Disorders. J Am Acad Child Adolesc Psychiatry. 2010;49(12):11891201. [Crossref]  [PubMed]  [PMC]
29. Zhang MWB, Ying J, Wing T, Song G, Fung DSS, Smith HE. Cognitive Biases in Cannabis, Opioid, and Stimulant Disorders: A Systematic Review. Front Psychiatry. 2018;9:376. [Crossref]  [PubMed]  [PMC]
30. DeVito EE, Kiluk BD, Nich C, Mouratidis M, Carroll KM. Drug Stroop: Mechanisms of response to computerized cognitive behavioral therapy for cocaine dependence in a ran domized clinical trial. Drug Alcohol Depend. 2018;183:162-168. [Crossref]  [PubMed]  [PMC]
31. Melugin PR, Nolan SO, Siciliano CA. Bidirectional causality between addiction and cognitive deficits. In: International Review of Neurobiology. Vol 157. Elsevier; 2021:371-407. [Crossref]  [PubMed]  [PMC]
32. Chen S, Yang P, Chen T, Su H, Jiang H, Zhao M. Risky decision-making in individuals with substance use disorder: A meta-analysis and meta-regression review. Psychopharmacology (Berl). 2020;237(7):1893-1908. [Crossref]  [PubMed]
33. Valyan A, Ekhtiari H, Smith R, Paulus MP. Decision-making deficits in substance use disorders. In: Cognition and Addiction. Elsevier; 2020:25-61. [Crossref]  [PubMed]
34. Bechara A, Damasio H. Decision-making and addiction (part I): impaired activation of somatic states in substance dependent individuals when pondering decisions with negative future consequences. Neuropsychologia. 2002;40(10):16751689. [Crossref]  [PubMed]
35. Verdejo-Garcia A, Perez-Garcia M, Bechara A. Emotion, Decision-Making and Substance Dependence:ASomatic-Marker Model of Addiction. Curr Neuropharmacol. 2006;4(1):17-31. [Crossref]  [PubMed]  [PMC]
36. Bickel WK, Jarmolowicz DP, Mueller ET, Koffarnus MN, Gatchalian KM. Excessive discounting of delayed reinforcers as a trans-disease process contributing to addiction and other disease-related vulnerabilities: Emerging evidence. Pharmacol Ther. 2012;134(3):287-297. [Crossref]  [PubMed]  [PMC]
37. Lim TV, Ersche KD. Goal-Directed and Habitual Control in Human Drug Addiction. In: Vandaele Y, ed. Habits. Springer International Publishing; 2024:251-272. [Crossref]  [PubMed]
38. Zilverstand A, Huang AS, Alia-Klein N, Goldstein RZ. Neuroimaging Impaired Response Inhibition and Salience Attribution in Human Drug Addiction: A Systematic Review. Neuron. 2018;98(5):886-903. [Crossref]  [PubMed]  [PMC]
39. Hanegraaf L, Van Baal S, Hohwy J, Verdejo-Garcia A. A systematic review and meta-analysis of ‘Systems for Social Processes’ in borderline personality and substance use disorders. Neurosci Biobehav Rev. 2021;127:572-592. [Crossref]  [PubMed]
40. Castellano F, Bartoli F, Crocamo C, et al. Facial emotion recognition in alcohol and substance use disorders: A meta-analysis. Neurosci Biobehav Rev. 2015;59:147-154. [Crossref]  [PubMed]
41. Cservenka A, Donahue LC. Emotion Recognition and Self-Reported Emotion Processing in Alcohol and Cannabis Co-Using Young Adults. Behav Sci. 2024;14(5):407. [Crossref]  [PubMed]  [PMC]
42. Cox SS, Reichel CM. The intersection of empathy and addiction. Pharmacol Biochem Behav. 2023;222:173509. [Crossref]  [PubMed]  [PMC]
43. Winters DE, Brandon-Friedman R, Yepes G, Hinckley JD. Systematic review and meta-analysis of socio-cognitive and socio-affective processes association with adolescent substance use. Drug Alcohol Depend. 2021;219:108479. [Crossref]  [PubMed]  [PMC]
44. Guerin AA, Bonomo Y, Lawrence AJ, et al. Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research. Front Psychiatry. 2019;10:880. [Crossref]  [PubMed]  [PMC]
45. Neelamegam M, Zgibor J, Chen H, et al. The effect of opioids on the cognitive function of older adults: results from the Personality and Total Health through life study. Age Ageing. 2021;50(5):1699-1708. [Crossref]  [PubMed]  [PMC]
46. Baldacchino A, Balfour DJK, Passetti F, Humphris G, Matthews K. Neuropsychological consequences of chronic opioid use: A quantitative review and meta-analysis. Neurosci Biobehav Rev. 2012;36(9):2056-2068. [Crossref]  [PubMed]
47. Wollman SC, Hauson AO, Hall MG, et al. Neuropsychological functioning in opioid use disorder: A research synthesis and meta-analysis. Am J Drug Alcohol Abuse. 2019;45(1):11-25. [Crossref]  [PubMed]
48. Pignolo RJ. Opioids and Accelerated Brain Aging: The White Matter Matters. Mayo Clin Proc. 2024;99(5):691692. [Crossref]  [PubMed]
49. Cole RH, Moussawi K, Joffe ME. Opioid modulation of prefrontal cortex cells and circuits. Neuropharmacology. 2024;248:109891. [Crossref]  [PubMed]  [PMC]
50. Potvin S, Pelletier J, Grot S, Hébert C, Barr AM, Lecomte T. Cognitive deficits in individuals with methamphetamine use disorder: A meta-analysis. Addict Behav. 2018;80:154-160. [Crossref]  [PubMed]
51. Winhusen T, Lewis D, Adinoff B, et al. Impulsivity is associated with treatment non-completion in cocaineand methamphetamine-dependent patients but differs in nature as a function of stimulant-dependence diagnosis. J Subst Abuse Treat. 2013;44(5):541-547. [Crossref]  [PubMed]  [PMC]
52. Mahoney JJ. Cognitive dysfunction in individuals with cocaine use disorder: Potential moderating factors and pharmacological treatments. Exp Clin Psychopharmacol. 2019;27(3):203-214. [Crossref]  [PubMed]  [PMC]
53. Heilbronner SR, Meck WarrenH. Dissociations between interval timing and intertemporal choice following administration of fluoxetine, cocaine, or methamphetamine. Behav Processes. 2014;101:123-134. [Crossref]  [PubMed]  [PMC]
54. Burggren AC, Shirazi A, Ginder N, London ED. Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives. Am J Drug Alcohol Abuse. 2019;45(6):563-579. [Crossref]  [PubMed]  [PMC]
55. Lovell ME, Akhurst J, Padgett C, Garry MI, Matthews A. Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: A meta-analysis. Exp Clin Psychopharmacol. 2020;28(4):471-494. [Crossref]
56. Scott JC, Slomiak ST, Jones JD, Rosen AFG, Moore TM, Gur RC. Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2018;75(6):585. [Crossref]  [PubMed]  [PMC]
57. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Nonacute (residual) neurocognitive effects of cannabis use: A meta-analytic study. J Int Neuropsychol Soc. 2003;9(5):679689. [Crossref]  [PubMed]
58. Bonnieux JN, VanderZwaag B, Premji Z, Garcia-Romeu A, Garcia-Barrera MA. Psilocybin’s effects on cognition and creativity: A scoping review. J Psychopharmacol (Oxf). 2023;37(7):635-648. [Crossref]  [PubMed]  [PMC]
59. Roberts CA, Jones A, Montgomery C. Meta-analysis of executive functioning in ecstasy/polydrug users. Psychol Med. 2016;46(8):1581-1596. [Crossref]  [PubMed]  [PMC]
60. Zhang C, Tang WK, Liang HJ, Ungvari GS, Lin SK. Other drug use does not impact cognitive impairments in chronic ketamine users. Drug Alcohol Depend. 2018;186:1-8. [Crossref]  [PubMed]
61. Savolainen K, Ihalainen J, Hämäläinen E, Tanila H, Forsberg MM. Phencyclidine-induced cognitive impairments in repeated touchscreen visual reversal learning tests in rats. Behav Brain Res. 2021;404:113057. [Crossref]  [PubMed]
62. Morgan CJA, Dodds CM, Furby H, et al. Long-Term Heavy Ketamine Use is Associated with Spatial Memory Impairment and Altered Hippocampal Activation. Front Psychiatry. 2014;5. [Crossref]  [PubMed]  [PMC]
63. Kalopita K, Armakolas A, Philippou A, Zarros A, Angelogianni P. Ketamine-induced neurotoxicity in neurodevelopment: A synopsis of main pathways based on recent in vivo experimental findings. J Anaesthesiol Clin Pharmacol. 2021;37(1):37-42. [Crossref]  [PubMed]  [PMC]
64. Zimmermann J, Zölch N, Coray R, et al. Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use Is Related to Glutamate and GABA Concentrations in the Striatum But Not the Anterior Cingulate Cortex. Int J Neuropsychopharmacol. 2023;26(6):438-450. [Crossref]  [PubMed]  [PMC]
65. Crowe SF, Stranks EK. The Residual Medium and Longterm Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis. Arch Clin Neuropsychol. 2018;33(7):901911. [Crossref]  [PubMed]
66. Liu L, Jia L, Jian P, et al. The Effects of Benzodiazepine Use and Abuse on Cognition in the Elders: A Systematic Review and Meta-Analysis of Comparative Studies. Front Psychiatry. 2020;11:00755. [Crossref]  [PubMed]  [PMC]
67. Vermeeren A, Coenen AML. Effects of the use of hypnotics on cognition. In: Progress in Brain Research. Vol 190. Elsevier; 2011:89-103. [Crossref]  [PubMed]
68. Haghparast P, Pondrom M, Ray SD. Sedatives and hypnotics. In: Side Effects of Drugs Annual. Vol 42. Elsevier; 2020:67-79. [Crossref]  [PubMed]
69. Radparvar S. The Clinical Assessment and Treatment of Inhalant Abuse. Perm J. 2023;27(2):99-109. [Crossref]  [PubMed]  [PMC]
70. Woodward JJ, Braunscheidel KM. The Effects of the Inhalant Toluene on Cognitive Function and Behavioral Flexibility: A Review of Recent Findings. Addict Neurosci. 2023;5:100059. [Crossref]  [PubMed]  [PMC]
71. Hernández-Álvarez DM, Pacheco L, Velasco-Segura R, Pérez De La Mora M, Tejeda-Romero C, GonzálezGarcía N. Default Mode Network Efficiency Is Correlated With Deficits in Inhibition in Adolescents With Inhalant Use Disorder. Front Psychiatry. 2020;11:209. [Crossref]  [PubMed]  [PMC]
72. Yokoyama J, Diep S, Kiyokawa M, Onoye J. Inhalant Screening in Early Adolescence: Missed Opportunity to Prevent Escalation to Polysubstance Use and Related Consequences. Prim Care Companion CNS Disord. 2024;26(2). [Crossref]  [PubMed]
73. Malloul H, Bennis M, Bonzano S, et al. Decreased Hippocampal Neuroplasticity and Behavioral Impairment in an Animal Model of Inhalant Abuse. Front Neurosci. 2018;12:35. [Crossref]  [PubMed]  [PMC]